Russia closes in on developing its first anti-COVID-19 drug

30 November 2021

Russia is getting closer to the completion of development of one of the world’s first drugs against COVID-19, according to recent statements by the Russian Health Minister Mikhail Murashko and some local media, reports The Pharma Letter’s local correspondent.

According to Forbes Russia, the drug is known as MIR-19, and is seen to work by blocking the ability of the virus to replicate. Mr Murashko also added that the drug interrupts the course of the disease at the initial stage of infection.

Forbes Russia reported citing its sources, the drug was developed by the Institute of Immunology of the Federal Medical and Biological Agency (FMBA), one of Russia’s leading research institutions in the field of immunology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK